Prostatic intraepithelial neoplasia: Animal models 2000

Prostate

Volumn 43, Issue 4, 2000, Pages 286-294

  Bostwick, David G ^a,b,c,d   Ramnani, Dharam ^a,b,c   Qian, Junqi ^a  

^a BOSTWICK LABORATORIES   (United States)

^b Urology of Virginia   (United States)

^c Virginia Urology Center   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARCINOMA IN SITU; DOG; HISTOPATHOLOGY; MALE; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE TUMOR; RAT; SPECIES DIFFERENCE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; HUMANS; MALE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0034213621     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20000601)43:4<286::AID-PROS8>3.0.CO;2-0     Document Type: Article

References (22)

1. McNeal JE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 1986;17:64-71.
2. Bostwick DG, Brawer MK. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 1987;59:788-794.
3. Bostwick DG. Prostatic intraepithelial neoplasia is a risk factor for cancer. Semin Urol Oncol 1999;17:187-198.
4. Waters DJ, Sakr WA, Hayden DW, Lang CM, McKinney L, Murphy GP, Radinsky R, Ramoner R, Richardson RC, Tindall DJ. Workgroup 4: spontaneous prostate carcinoma in dogs and nonhuman primates. Prostate 1998;36:64-67.
5. Waters DJ, Bostwick DG. Prostatic intraepithelial neoplasia occurs spontaneously in the canine prostate. J Urol 1997;157:713-716.
6. Waters DJ, Patronek GJ, Bostwick DG, Glickman LT. Comparing the age at prostate cancer diagnosis in humans and dogs. J Natl Cancer Inst 1996;20;88:1686-1687.
7. Green JE, Greenberg NM, Ashendel CL, Barrett JC, Boone C, Getzenberg RH, Henkin J, Matusik R, Janus TJ, Scher HI. Workgroup 3: transgenic and reconstitution models of prostate cancer. Prostate 1998;36:59-63.
8. Bosland MC, Chung LWK, Greenberg NM, Ho S, Isaacs JT, Lane K, Peehl DM, Thompson TC, van Steenbrugge GJ, van Weerden WM. Recent advances in the development of animal and cell culture models for prostate cancer research. A minireview. Urol Oncol 1996;2:99-128.
9. Thompson TC. Mouse prostate reconstitution: an in vivo transgenic gland model system. Urol Oncol 1996;2:99-128.
10. Garabedian EM, Humphrey PA, Gordon JI. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc Natl Acad Sci USA 1998;95:15382-15387.
11. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai N, Young P, Norton CR, Gridley T, Cardiff RD, Cunha GR, Abate-Shen C, Shen MM. Roles for Nkx3.1 in prostate development and cancer. Genes Dev 1999;13:966-977.
12. Pu YS, Luo W, Lu HH, Greenberg NM, Lin SH. Differential expression of C-CAM cell adhesion molecule in prostate carcinogenesis in a transgenic mouse model. J Urol 1999;162:892-896.
13. Pollard M. Lobund-Wistar rat model of prostate cancer. Prostate 1998;37:1-4.
14. Lucia MS, Bostwick DG, Bosland M, Cockert AT, Knapp DW, Leav I, Pollard M, Rinker-Schaeffer C, Shirai T, Watkins BA. Workgroup I: rodent models of prostate cancer. Prostate 1998;36:49-55.
15. Wang YZ, Wong YC. Sex hormone-induced prostatic carcinogenesis in the Noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate 1998;35:165-177.
16. Pollard M. Commentary on the Dunning tumor. Prostate 1995; 26:287-289.
17. Isaacs JT. The R-3327 system of rat prostatic cancers. Urol Oncol 1996;2:115-116.
18. Geldof AA, Rao BR. Prostatic tumor (R3327) skeletal metastasis. Prostate 1990;16:279-290.
19. Goebel HW, Rausch U, Steinhoff M, Seitz J, Bacher M, Papotti M, Bussolati G, Tuohimaa P, Aumuller G. Arguments against the prostatic origin of the R-3327 Dunning H tumor. Virchows Arch [B] 1992;62:9-18.
20. Clements J, Ward G, Kaushal A, Hi S-I, Kennett C, Nicol D. A prostate-specific antigen-like protein associated with renal cell carcinoma in women. Clin Cancer Res 1997;3:1427-1431.
21. Bao L, Loda M, Janmey PA, Stewart R, Anand-Apte B, Zetter BR. Thymosin beta 15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer. Nat Med 1996;2:1322-1328.
22. Bosland MC. Use of animal models in defining efficacy of chemoprevention agents against prostate cancer. Eur Urol 1999;35: 459-463.